The oral bacterial microbiota facilitates the stratification for ulcerative colitis patients with oral ulcers.
Bacterial microbiota
Oral ulcer
Response
Stratification
Ulcerative colitis
Journal
Annals of clinical microbiology and antimicrobials
ISSN: 1476-0711
Titre abrégé: Ann Clin Microbiol Antimicrob
Pays: England
ID NLM: 101152152
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
13
07
2023
accepted:
24
10
2023
medline:
13
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
epublish
Résumé
Clinically, a large part of inflammatory bowel disease (IBD) patients is complicated by oral lesions. Although previous studies proved oral microbial dysbiosis in IBD patients, the bacterial community in the gastrointestinal (GI) tract of those IBD patients combined with oral ulcers has not been profiled yet. In this study, we enrolled four groups of subjects, including healthy controls (CON), oral ulcer patients (OU), and ulcerative colitis patients with (UC_OU) and without (UC) oral ulcers. Bio-samples from three GI niches containing salivary, buccal, and fecal samples, were collected for 16S rRNA V3-V4 region sequencing. Bacterial abundance and related bio-functions were compared, and data showed that the fecal microbiota was more potent than salivary and buccal microbes in shaping the host immune system. ~ 22 UC and 10 UC_OU 5-aminosalicylate (5-ASA) routine treated patients were followed-up for six months; according to their treatment response (a decrease in the endoscopic Mayo score), they were further sub-grouped as responding and non-responding patients. We found those UC patients complicated with oral ulcers presented weaker treatment response, and three oral bacterial genera, i.e., Fusobacterium, Oribacterium, and Campylobacter, might be connected with treatment responding. Additionally, the salivary microbiome could be an indicator of treatment responding in 5-ASA routine treatment rather than buccal or fecal ones. The fecal microbiota had a strong effect on the host's immune indices, while the oral bacterial microbiota could help stratification for ulcerative colitis patients with oral ulcers. Additionally, the oral microbiota had the potential role in reflecting the treatment response of UC patients. Three oral bacteria genera (Fusobacterium, Oribacterium, and Campylobacter) might be involved in UC patients with oral ulcers lacking treatment responses, and monitoring oral microbiota may be meaningful in assessing the therapeutic response in UC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Clinically, a large part of inflammatory bowel disease (IBD) patients is complicated by oral lesions. Although previous studies proved oral microbial dysbiosis in IBD patients, the bacterial community in the gastrointestinal (GI) tract of those IBD patients combined with oral ulcers has not been profiled yet.
METHODS
METHODS
In this study, we enrolled four groups of subjects, including healthy controls (CON), oral ulcer patients (OU), and ulcerative colitis patients with (UC_OU) and without (UC) oral ulcers. Bio-samples from three GI niches containing salivary, buccal, and fecal samples, were collected for 16S rRNA V3-V4 region sequencing. Bacterial abundance and related bio-functions were compared, and data showed that the fecal microbiota was more potent than salivary and buccal microbes in shaping the host immune system. ~ 22 UC and 10 UC_OU 5-aminosalicylate (5-ASA) routine treated patients were followed-up for six months; according to their treatment response (a decrease in the endoscopic Mayo score), they were further sub-grouped as responding and non-responding patients.
RESULTS
RESULTS
We found those UC patients complicated with oral ulcers presented weaker treatment response, and three oral bacterial genera, i.e., Fusobacterium, Oribacterium, and Campylobacter, might be connected with treatment responding. Additionally, the salivary microbiome could be an indicator of treatment responding in 5-ASA routine treatment rather than buccal or fecal ones.
CONCLUSIONS
CONCLUSIONS
The fecal microbiota had a strong effect on the host's immune indices, while the oral bacterial microbiota could help stratification for ulcerative colitis patients with oral ulcers. Additionally, the oral microbiota had the potential role in reflecting the treatment response of UC patients. Three oral bacteria genera (Fusobacterium, Oribacterium, and Campylobacter) might be involved in UC patients with oral ulcers lacking treatment responses, and monitoring oral microbiota may be meaningful in assessing the therapeutic response in UC patients.
Identifiants
pubmed: 37946238
doi: 10.1186/s12941-023-00646-3
pii: 10.1186/s12941-023-00646-3
pmc: PMC10633958
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Mesalamine
4Q81I59GXC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
99Subventions
Organisme : the Beijing Municipal Natural Science Foundation
ID : No. 7214267
Organisme : the Beijing Municipal Natural Science Foundation
ID : No. 7232196
Organisme : the National Natural Science Foundation of China
ID : No. 82000496
Organisme : the National Natural Science Foundation of China
ID : No. 82070539
Organisme : Peking University People's Hospital Scientific Research Development Funds
ID : No. RDY2020-21
Organisme : Peking University People's Hospital Scientific Research Development Funds
ID : No. PTU2021-03
Organisme : the Beijing Science and technology planning project
ID : No. Z171100000417022
Informations de copyright
© 2023. The Author(s).
Références
Cell Microbiol. 2020 Aug;22(8):e13210
pubmed: 32329205
Endocr Connect. 2019 Jul;8(7):822-828
pubmed: 31137015
Bioinformatics. 2014 Nov 1;30(21):3123-4
pubmed: 25061070
Gut Microbes. 2022 Jan-Dec;14(1):2044723
pubmed: 35239463
Pharmacol Res. 2021 Jul;169:105654
pubmed: 33964469
Adv Rheumatol. 2021 Jul 2;61(1):42
pubmed: 34215348
Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):111-128
pubmed: 29018272
Int Arch Allergy Immunol. 2012;157(2):194-201
pubmed: 21986191
Nat Commun. 2019 Apr 5;10(1):1554
pubmed: 30952846
Front Microbiol. 2018 May 30;9:1136
pubmed: 29899737
Ann Intern Med. 2017 Jul 04;167(1):34-39
pubmed: 28531908
Free Radic Biol Med. 2012 Jan 1;52(1):182-90
pubmed: 22067901
Nature. 2020 May;581(7809):475-479
pubmed: 32461639
Nat Rev Microbiol. 2016 Jan;14(1):20-32
pubmed: 26499895
Int J Mol Sci. 2021 Aug 08;22(16):
pubmed: 34445234
Sci Rep. 2016 Oct 13;6:35216
pubmed: 27734914
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
J Clin Gastroenterol. 2016 Nov/Dec;50(10):803-818
pubmed: 27741097
Cell. 2020 Jul 23;182(2):447-462.e14
pubmed: 32758418
J Immunol. 2021 Mar 15;206(6):1181-1193
pubmed: 33547171
J Crohns Colitis. 2019 Oct 28;13(11):1439-1449
pubmed: 31066440
Cell Host Microbe. 2019 May 8;25(5):668-680.e7
pubmed: 31071294
Gut. 2015 Mar;64(3):447-58
pubmed: 24811995
Gut. 2015 Oct;64(10):1650-68
pubmed: 26342014
Nat Methods. 2013 Oct;10(10):996-8
pubmed: 23955772
Nature. 2017 Nov;551(7681):S94-S95
pubmed: 32080572
Science. 2017 Oct 20;358(6361):359-365
pubmed: 29051379
Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):731-742
pubmed: 34400822
Nature. 2017 Oct 5;550(7674):61-66
pubmed: 28953883
mBio. 2021 Mar 2;12(2):
pubmed: 33653893
Curr Opin Gastroenterol. 2017 Nov;33(6):422-427
pubmed: 28877044
J Genet Genomics. 2022 Feb;49(2):155-164
pubmed: 34537414
Nucleic Acids Res. 2021 Jan 8;49(D1):D545-D551
pubmed: 33125081
N Engl J Med. 2020 Feb 27;382(9):822-834
pubmed: 32101664
J Gastroenterol Hepatol. 2018 Feb 20;:
pubmed: 29462845
Dig Dis Sci. 2022 Jan;67(1):42-55
pubmed: 33527328
Int J Mol Sci. 2021 Sep 03;22(17):
pubmed: 34502474
Gastroenterology. 2019 Oct;157(4):1081-1092.e3
pubmed: 31175864
Microbiol Mol Biol Rev. 2019 Jun 5;83(3):
pubmed: 31167904
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Nucleic Acids Res. 2014 Jan;42(Database issue):D633-42
pubmed: 24288368
Front Immunol. 2021 Jan 06;11:579615
pubmed: 33488580
Gut Microbes. 2020 Nov 9;12(1):1-16
pubmed: 33054518
WMJ. 2021 Jul;120(2):145-147
pubmed: 34255956
Mol Cell Biol. 2015 May;35(10):1848-59
pubmed: 25776554
Sheng Li Xue Bao. 2020 Jun 25;72(3):308-324
pubmed: 32572429
Gut Microbes. 2021 Jan-Dec;13(1):1-21
pubmed: 33525961
Immunology. 2019 Dec;158(4):267-280
pubmed: 31509239
Inflamm Bowel Dis. 2011 Sep;17(9):1971-8
pubmed: 21830275
Inflamm Bowel Dis. 2020 Feb 11;26(3):380-390
pubmed: 31750918
Nat Biotechnol. 2013 Sep;31(9):814-21
pubmed: 23975157
Gut. 2020 Jul;69(7):1355-1356
pubmed: 31227588
Microbiome. 2021 Jun 28;9(1):148
pubmed: 34183060
DNA Res. 2014 Feb;21(1):15-25
pubmed: 24013298
Front Microbiol. 2018 Jun 13;9:1274
pubmed: 29951050
Biochemistry. 2014 Feb 11;53(5):821-35
pubmed: 24460461
BMC Gastroenterol. 2021 Mar 5;21(1):105
pubmed: 33663411
BMC Genomics. 2019 Nov 14;20(1):862
pubmed: 31726978
Nat Rev Immunol. 2009 May;9(5):313-23
pubmed: 19343057
BMC Biol. 2021 Nov 6;19(1):240
pubmed: 34742306
Br Dent J. 2017 Jan 13;222(1):53-57
pubmed: 28084352
Front Oncol. 2020 Aug 12;10:1418
pubmed: 32903396
Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):6
pubmed: 34857938
Mucosal Immunol. 2019 Jul;12(4):843-850
pubmed: 30976087
Curr Protoc. 2021 Nov;1(11):e294
pubmed: 34807525